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CHARACTERIZATION OF A HEPATITIS B VIRUS STRAIN IN SOUTHWESTERN PARANÁ, BRAZIL, 
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SUMMARY
The present study investigated if hepatitis B virus (HBV) mutants circulate in the southwestern region of the State of Paraná, 
Brazil, by analyzing samples from children who received immunoprophylaxis but were born to HBV carrier mothers. Samples from 25 
children were screened for HBV serum markers and for HBV DNA by PCR. Only one sample was positive for HBsAg, anti-HBs and 
HBV DNA, although the child had been vaccinated. Analysis of the S gene sequence of this sample showed the presence of a proline 
at position 105, a serine at position 114, three threonines at positions 115, 116 and 140, and a glutamine at position 129. The presence 
of these amino acids, except for serine at position 114, has been related to monoclonal or polyclonal therapy with anti-HBs after liver 
transplantation, whereas the presence of threonine at position 116 has been described in immunized children from Singapore. This 
finding demonstrates the possible circulation of HBV strains resistant to hepatitis B immunoprophylaxis in southwestern Paraná, Brazil. 
The genotype of the sample was identified as genotype D, which is frequently found in the region studied. Since 36% of the children 
had received incomplete or no immunoprophylaxis, more extensive follow-up of children born to HBsAg-positive mothers is needed. 
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INTRODUCTION
Hepatitis B virus (HBV) belongs to the genus Orthohepadnavirus, 
family Hepadnaviridae. HBV infection is one of the major global 
public health problems. Among the approximately two billion people 
infected worldwide, more than 350 million are chronic HBV carriers33. 
Approximately 400,000 new cases are estimated to occur in Latin 
America each year12.
HBV is characterized by its wide genetic variability. These genetic 
differences have led to the classification of the HBV into eight genotypes 
(A-H), which are divided into subgenotypes with distinct virological and 
epidemiological properties26. Few genotype data are available in Brazil, 
but it is known that A, D and F are the main genotypes circulating in the 
country. MELLO et al. (2007) identified genotypes A, D and F among 
303 HBV isolates which were obtained from all geographic regions of 
Brazil, genotype D being the most prevalent in the south region (84.2%). 
SITNIK et al. (2004), studying 103 samples from patients with chronic 
hepatitis B originating from different regions of Brazil, found genotypes 
A (49.5%), B (2.9%), C (13.6%), D (24.3%), and F (9.7%). In Paraná, 
genotypes A (14.0%), C (1.3%), D (82.9%), F (1.3%) and H (0.4%) were 
identified in samples from HBsAg-positive blood donors (BERTOLINI 
et al., unpublished data).
Hepatitis B is an important disease in the State of Paraná, Brazil9,10,28. 
An intermediate prevalence has been recently observed in Cascavel, Foz 
do Iguaçu and Francisco Beltrão3. Vaccination of risk groups started in 
1991 but had no impact on infection control. Children under one year 
of age were vaccinated in 1995, when the hepatitis B vaccine was first 
introduced in the National Immunization Program throughout Brazil. 
Whereas in 1998 the vaccine was applied to children under 15 years of 
age only in the southwestern region of the State of Paraná, vaccination 
was extended to all states in 1999. In 2001, the age range comprised 
individuals under 21 years of age18. The measures mentioned above led 
to a rapid decline in the incidence of hepatitis B in the under-15-year-
old population. Preliminary results show that vaccination strategies are 
effective in the control of hepatitis B in a certain age group18.
The exposure of the host’s immune system to viral surface antigen 
(HBsAg) during HBV infection provides an important basis for the 
protective response against the virus. However, HBsAg exposure, together 
with the fact that HBV has a mutation rate ten times higher than that of 
other DNA viruses15, favors the emergence of mutations in the surface 
(S) gene. Data regarding the primary structure of HBsAg in different 
regions of the world are important for the understanding of failure of 
protection with current vaccines21. 
Point mutations in the S gene that result in amino acid substitutions 
in the common “a” antigenic determinant, which lies between amino 
acids 124 and 147, can alter B-cell epitopes of HBsAg, leading 
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to variants that escape from the host immune response elicited by 
vaccination or previous infection16. WALLACE & CARMAN (1997) 
suggested increasing the area of investigation in the “S” region to 
include the entire major hydrophilic region (MHR) which comprises 
amino acids 99 to 169. The authors proposed the following system 
for the classification of mutations into five regions: HBs1, region 
upstream of amino acid 120; HBs2, region comprising amino acids 
120 to 123; HBs3, region comprising amino acids 124 to 137; HBs4, 
region comprising amino acids 138 to 147, and HBs5, region comprising 
amino acids 148 to 169.
The most common HBsAg variant associated with resistance to 
vaccine-induced anti-HBs is a glycine-to-arginine substitution at amino 
acid 145 of the MHR of protein S4,24,31. Vaccine-associated variants have 
been demonstrated in Italy4, the United Kingdom20, the United States19, 
Singapore13, Taiwan16,22, Senegal11, India29, Indonesia5, and Japan24. 
The following vaccine-associated HBsAg mutations were identified: 
I110V, T/I126N, Q129H, M133L, K141E, P142S, D144A, G145R, and 
C149R6,7,32. OON et al. (1999) detected various previously unknown 
mutations outside the region of the “a” determinant in immunized children 
from Singapore (N116T, V118A, A159V, F183C, and V184A). Recently, 
ARAÚJO et al. (2008) reported the presence of a single amino acid 
substitution, L215Q, in genotype F which may affect the conformation 
of HBsAg, possibly causing defective insertion in the endoplasmic 
reticulum membrane and intracellular retention.
Vaccine-induced escape mutants of the HBV S gene pose a high 
risk to society since the use of hepatitis B immunoglobulins (HBIG) and 
vaccines are not effective in preventing infection. Blood units containing 
HBV mutants are not detected by routine screening for HBsAg and may 
transmit HBV infection to recipients of blood transfusions. Since these 
mutants may actively replicate even in the presence of a powerful anti-
HBc response in the host, the exclusion of blood units with high anti-HBc 
titers is expected to be effective in the prevention of their transmission 
by transfusion31.
Preliminary studies have detected mutations associated with 
vaccine resistance in HBV strains isolated from blood donors from the 
southeastern region of the State of Paraná2,3. This fact emphasizes the 
urgent need to determine the presence of HBV mutants in children. 
Progression of the disease in children has serious consequences since it 
maintains infection within the population. 
Therefore, the objective of the present study was to investigate if 
HBV mutants associated with resistance to vaccine and HBIG circulate 
in the southwestern region of the State of Paraná.
PATIENTS AND METHODS
Patients: A total of 123 children from the 8th Regional Health 
Division of the municipality of Francisco Beltrão were studied. These 
children were tested for HBIG between 1998 and 2004, but only 25 were 
located for the collection of biological material. 
A blood sample (5-10 mL) was collected from each of the 25 children 
with disposable syringes under aseptic conditions. After serum separation 
the samples were divided into two tubes and stored in a freezer at -20 
ºC until the time of use.
The study was approved by the Ethics Committee on Human 
Research of the State University of Maringá, and written informed 
consent was obtained from all mothers. 
Serology for HBV: Serum HBV markers (HBsAg, total anti-
HBc, anti-HBc IgM and anti-HBs) were analyzed by microparticle 
immunoassay using commercial kits (Abbott Laboratories, Abbott Park, 
Illinois, USA) in an AXSYM device (Abbott Laboratories) according to 
manufacturer specifications.
Amplification of the HBV S gene region by the Polymerase Chain 
Reaction (PCR): All samples were submitted to PCR amplification of 
the HBV S gene region, i.e., the region of the viral genome containing 
the MHR, thus permitting the identification of mutations that confer 
resistance to vaccine and HBIG. 
HBV DNA was extracted from 100 µL serum in a 300 µL guanidine 
isothiocyanate solution. Two primer sets were used for nested PCR: 
FHBS1 (5’ GAG TCT AGA CTC GTG GTG GAC TTC 3’) and RHBS1 
(5’ AAA TKG CAC TAG TAA ACT GAG CCA 3’) for the first reaction, 
and FHBS2 (5’ CGT GGT GGA CTT CTC TCA ATT TTC 3’) and 
RHBS2 (5’ GCC ARG AGA AAC GGR CTG AGG CCC 3’) for the 
second reaction. The primers occupy the following positions in the 
HBV genome (strain HBVADW; GenBank accession number V00866): 
HBS1F (positions 244 to 267), HBS2F (positions 255 to 278), HBS2R 
(positions 648 to 671), and HBS1R (positions 668 to 691). The two 
reactions were carried out in a thermocycler (TPersonal Thermocycler, 
Biometra) programmed as follows: one cycle at 94 oC for 30 s for initial 
denaturation, 35 cycles at 94 oC for 20 s (denaturation), 56 oC for 20 s 
(annealing), and 72 oC for 30 s (extension), and one cycle at 72 oC for five 
min. The samples were stored at 4 ºC for an indeterminate period of time27.
After amplification in duplicate, the nested PCR product was 
identified by electrophoresis on 1.0% agar gel stained with ethidium 
bromide and photographed with a Polaroid camera. Samples were 
classified as positive when they presented a band with a molecular 
weight close to 450 bp.
Sequencing of the S gene region: The nested PCR products were 
sequenced in duplicate using dideoxyribonucleotide triphosphates 
(ddNTPs) labeled with fluorescent markers. Sequencing reactions were 
performed using the ABI Prism BigDyeTM Terminator Cycle Sequencing 
kit (PE Applied Biosystems, Foster City, CA) in an automatic ABI Prism 
377 sequencer (PE Applied Biosystems). Sequences were analyzed in 
both directions (forward and reverse) using primers FHBS2 and RHBS2.
HBV genotyping: The EditSeq and Megalign programs of the 
DNAstar package (Lasergene Inc., USA) were used for the analysis, 
correction and alignment of nucleotide and amino acid sequences. The 
accession number of the strain in GenBank is FJ613840. 
The genotype was classified by alignment of the nucleotide sequence 
of the S gene with 53 already known sequences of 8 HBV genotypes 
(A-H), deposited at DDBJ/EMBL/GenBank (Table 1). Sequences were 
aligned using the CLUSTAL method14 and the PAM250 weight residue 
table.
Identification of mutations in the S gene region causing resistance 
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to vaccine and HBIG: Mutations were identified and compared with 
mutations described in the literature as resistant to vaccine and to HBIG.
RESULTS
Of the 25 children born to HBsAg-positive mothers, five (20%) were 
from the municipality of Capanema, four (16%) were from Cascavel, five 
(20%) from Francisco Beltrão, three (12%) from Salto do Lontra, two 
(8%) from Santo Antônio do Sudoeste, one (4%) from Verê, three (12%) 
from Dois Vizinhos, and two (8%) from Enéas Marques. Fifteen (60%) 
children were female and 10 (40%) were male. Although the municipality 
of Cascavel does not belong to the 8th Regional Health Division, the 10th 
Regional Health Division participated voluntarily in the present study. 
The mean age of the children was 2.4 years.
Based on medical chart seven (28%) children had received vaccine 
only, two (8%) had received HBIG, only 15 (60%) had received 
the two types of immunoprophylaxis, and one child (4%) had not 
received any immunoprophylaxis. Thus, nine (36%) children received 
incomplete immunoprophylaxis and one child (4%) did not receive any 
immunoprophylaxis, although HBIG is requested at the 8th Regional 
Health Division.
Only one (5.3%) sample was simultaneously positive for HBsAg 
and anti-HBs. Another sample (5.3%) was not positive for any serum 
marker, although this child had been vaccinated. Three (15.8%) children 
who were positive for total anti-HBc and anti-HBs probably contracted 
HBV during intrauterine life and the infection was resolved.
All 25 children (100%) were investigated for the presence of HBV 
DNA by PCR and only one sample (4%) was positive (sample ALMLHBS), 
corresponding to the sample positive for HBsAg and anti-HBs. This child 
was born on May 31, 2004 and was vaccinated on June 1, 2004. The blood 
sample was collected on August 9, 2006. The PCR product of this sample 
was sequenced and genotyped. Analysis of mutations that might interfere 
with vaccine and HBIG immunogenicity showed the presence of a proline 
(P) at position 105, a serine (S) at position 114, three threonines (T) at 
positions 115, 116 and 140, and a glutamine (Q) at position 129 (Fig. 1). 
Substitution of glycine (G) with arginine (R) at position 145 (G145R) in 
the MHR of protein S, the most common HBsAg variant associated with 
resistance to vaccine-induced anti-HBs, was not found.
DISCUSSION
Although the amino acids found at positions 115 (T), 116 (T) and 
129 (Q) are considered to be conserved residues and amino acids located 
at positions 105 (P/HAS) and 140 (T/S) are non-conserved residues 
(SCHAEFER et al. 2005), the presence of a P at position 105, three T’s 
at positions 115, 116 and 140 and a Q at position 129 observed in the 
present study have been associated with monoclonal or polyclonal therapy 
with anti-HBs after liver transplantation, with these mutations tending 
to accumulate within and around the HBs2 and HBs4 regions6,7,8,25,32. 
Although mutation T114R has also been associated with monoclonal or 
polyclonal anti-HBs therapy after liver transplantation, a serine (S) was 
found at this position, which is a neutral polar amino acid like threonine 
(T). However, this finding does not imply tertiary structure alterations 
causing resistance to vaccine and HBIG. The presence of a T at position 
116 has been identified in immunized children from Singapore23.
The amino acid at position 140 (T/S) contributes to the classification 
of genotypes E and F, a fact that does not impair the analysis of the present 
results since genotype D was identified. 
The isolate was classified as genotype D by alignment of its amino 
acid sequence with 53 known sequences from 8 HBV genotypes (A-H) 
TABLE 1
Partial S gene sequences used for alignment to distinguish between the 
different HBV genotypes
Genotype Sequence (GenBank accession number)
A X75666, X75669, X65258, M54898, J02205, X51970, 
and M74498
B X75660, D23677, D23678, D00329, D00330, D00331, 
M54923, S74815, and S74867
C X75667, X75665, X75792, X75656, X01587, D23680, 
D23682, D23681, D16665, S62754, S75184, S81945, 
S81946, and U19777
D X75668, X75662, M32138, X77309, X65259, X59795, 
X68292, X77308, J02202, V01460, X02496, and X77310
E X75657, X75664, and L24071
F X75658, X75661, and X69798
G AF369533 and AF160501
H U91819, U91827, and AY090460
Fig. 1 - Nucleotide (378 bp) and amino acid sequence (125 aa) of the S gene region of a sample 
obtained from a PCR HBV-positive child from the municipality of Salto do Lontra, Paraná, 
Brazil, showing the positions of possible mutations associated with resistance to vaccine 
and HBIG (ALMLHBS - sample; box - position of aa 145; dotted box - mutations found).
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deposited in GenBank . Genotype D is the most prevalent in the southern 
region of Brazil17,27 and in the State of Paraná2.
The Technical Committee of the National Program of Immunization, 
National Health Foundation, Brazilian Ministry of Health30, has 
suspended the supply of HBIG to children born to HBsAg-positive 
mothers between July 2000 and October 2002. It was reported that the 
vaccine itself would provide the same protection. However, the nine 
(36%) children who received incomplete or no immunoprophylaxis were 
not born during this period.
Positivity for HBsAg and anti-HBs serum markers might be observed 
when the patient is in the resolution phase of the infection. The child with 
this serum marker profile was born on May 31, 2004 and only received the 
hepatitis B vaccine on June 1, 2004, a fact that might have contributed to 
infection. The child may have been infected during the period of sample 
collection for the present study. When HBV positivity was confirmed 
by analysis of serum markers and PCR, the Epidemiological Service of 
the municipality of Salto do Lontra was notified to guarantee medical 
follow-up. 
One child from the municipality of Cascavel, born on November 9, 
1997, was not positive for any of the serum markers analyzed, although 
the child had been vaccinated on February 3, 1998. One child (5.3%) 
was positive for hepatitis B by analysis of serum markers and PCR. The 
presence of amino acids P, T, T, Q and T at positions 105, 115, 116, 129 
and 140, respectively, may indicate the possibility of resistance to vaccine 
and HBIG. This fact shows that immunoprophylaxis-resistant HBV strains 
may circulate in the southwestern region of the State of Paraná, Brazil, 
Most children (n = 12, 63.2%) received complete hepatitis B 
immunoprophylaxis, including vaccine and HBIG. However, nine (36%) 
children received incomplete or no immunoprophylaxis, although they 
were born during a period other than that from July 2000 to October 
2002, a fact that may have exposed them to the HBV infection. 
Immunoprophylaxis of these children should be better controlled 
by health authorities to prevent the consequences of the disease and 
transmission of the infection.
RESUMO
Caracterização de uma cepa de hepatite por vírus B no sudoeste 
do Paraná, Brasil, apresentando mutações previamente associadas 
à resistência anti-HBs
O presente estudo investigou se mutantes do vírus da hepatite 
B (HBV) circulam na região Sudoeste do Estado do Paraná, Brasil, 
analisando amostras de crianças que receberam a imunoprofilaxia por 
terem nascido de mães portadoras do HBV. Amostras de 25 crianças 
foram analisadas para os marcadores sorológicos do HBV e para o 
DNA-HBV por PCR. Somente uma amostra foi positiva para AgHBs, 
anti-HBs e DNA-HBV, apesar da criança ter sido vacinada. Análises da 
seqüência do gene S desta amostra mostrou a presença de uma prolina 
na posição 105, uma serina na posição 114, três treoninas nas posições 
115, 116 e 140, e uma glutamina na posição 129. A presença destes 
aminoácidos, exceto para Serina na posição 114, tem sido relacionada 
a terapia monoclonal ou policlonal com anti-HBs após transplante de 
fígado, enquanto a presença da treonina na posição 116 tem sido descrita 
em crianças imunizadas de Singapura. Este achado demonstra a possível 
circulação de cepas do HBV resistentes a imunoprofilaxia para hepatite 
B no Sudoeste do Paraná, Brasil. O genótipo da amostra foi identificado 
como genótipo D, o qual é frequentemente encontrado na região estudada. 
Desde que 36% das crianças tinham recebido incompleta ou nenhuma 
imunoprofilaxia, um seguimento mais intensivo das crianças nascidas 
de mães AgHBs positivo é necessário.
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